// AST – IMS - [DMinute_ROS]

EPS for CBL & Associates Properties, (CBL) Expected At $0.45; American Physicians Service Group (AMPH)’s Sentiment Is 1

CBL & Associates Properties, Inc (NYSE:CBL) Logo

Analysts expect CBL & Associates Properties, Inc (NYSE:CBL) to report $0.45 EPS on February, 7 after the close.They anticipate $0.11 EPS change or 19.64% from last quarter’s $0.56 EPS. CBL’s profit would be $89.75M giving it 1.19 P/E if the $0.45 EPS is correct. After having $0.40 EPS previously, CBL & Associates Properties, Inc’s analysts see 12.50% EPS growth. The stock decreased 3.59% or $0.08 during the last trading session, reaching $2.15. About 547,356 shares traded. CBL & Associates Properties, Inc (NYSE:CBL) has declined 52.50% since January 14, 2018 and is downtrending. It has underperformed by 52.50% the S&P500. Some Historical CBL News: 26/04/2018 – CBL & ASSOCIATES PROPERTIES INC – PORTFOLIO OCCUPANCY WAS 91.1% AS OF MARCH 31, 2018, COMPARED WITH 92.1% AS OF MARCH 31, 2017; 26/04/2018 – CBL & Associates 1Q Loss/Shr 6c; 16/05/2018 – CBL Properties Announces New Entertainment Anchor at Jefferson Mall in Louisville, Kentucky; 23/03/2018 – CBL Properties Year-to-Date Sales off to Strong Start and Exceed National Average; 26/04/2018 – CBL & Associates Backs FY FFO $1.70/Shr-FFO $1.80/Shr; 26/04/2018 – CBL & ASSOCIATES PROPERTIES INC – SAME-CENTER MALL OCCUPANCY WAS 89.5% AS OF MARCH 31, 2018 COMPARED WITH 90.4% AS OF MARCH 31, 2017; 26/04/2018 – CBL & ASSOCIATES 1Q FFO/SHR AS ADJ 42C, EST. 43C; 26/04/2018 – CBL & Associates 1Q Loss $10.3M; 03/04/2018 – CBL Properties Announces First Phase Redevelopment Plans at Brookfield Square in Milwaukee, Wisconsin; 26/04/2018 – CBL & Associates 1Q FFO 42c/Shr

American Physicians Service Group Inc (AMPH) investors sentiment decreased to 1 in Q3 2018. It’s down -0.11, from 1.11 in 2018Q2. The ratio turned negative, as 43 institutional investors increased and started new positions, while 43 decreased and sold positions in American Physicians Service Group Inc. The institutional investors in our database now hold: 20.26 million shares, up from 19.80 million shares in 2018Q2. Also, the number of institutional investors holding American Physicians Service Group Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 14 Reduced: 29 Increased: 32 New Position: 11.

Analysts await Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings on March, 11. They expect $0.11 EPS, up 10.00% or $0.01 from last year’s $0.1 per share. AMPH’s profit will be $5.07 million for 49.55 P/E if the $0.11 EPS becomes a reality. After $0.12 actual EPS reported by Amphastar Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.

More notable recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Seekingalpha.com which released: “Amphastar Pharmaceuticals launches Primatene MIST – Seeking Alpha” on January 03, 2019, also Nasdaq.com with their article: “BHC vs. AMPH: Which Stock Is the Better Value Option? – Nasdaq” published on December 25, 2018, Seekingalpha.com published: “Amphastar beats by $0.01, beats on revenue – Seeking Alpha” on November 08, 2018. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) were released by: Nasdaq.com and their article: “Amphastar Pharmaceuticals (AMPH) Matches Q3 Earnings Estimates – Nasdaq” published on November 08, 2018 as well as Nasdaq.com‘s news article titled: “Amphastar Pharmaceuticals (AMPH) Misses Q2 Earnings Estimates – Nasdaq” with publication date: August 08, 2018.

The stock decreased 1.40% or $0.31 during the last trading session, reaching $21.8. About 25,367 shares traded. Amphastar Pharmaceuticals, Inc. (AMPH) has risen 20.09% since January 14, 2018 and is uptrending. It has outperformed by 20.09% the S&P500. Some Historical AMPH News: 21/03/2018 – AMPHASTAR SAYS COURT AFFIRMED JURY VERDICT FROM JULY 21, 2017; 10/05/2018 – Amphastar Closes Below 200-Day Moving Average: Technicals; 21/03/2018 – AMPHASTAR REPORTS FINAL JUDGMENT IN PATENT LITIGATION VS MOMENT; 21/03/2018 – AMPHASTAR PHARMACEUTICALS – DISTRICT COURT HELD THAT AMPHASTAR IS “PREVAILING PARTY” IN CASE, AFFIRMED JURY VERDICT, DATED JULY 21, 2017; 09/05/2018 – Amphastar Short-Interest Ratio Rises 78% to 18 Days; 09/05/2018 – Amphastar Pharmaceuticals 1Q Adj Loss/Shr 5c; 12/03/2018 – Amphastar Pharmaceuticals 4Q Adj EPS 10c; 13/03/2018 – AMPHASTAR PHARMACEUTICALS INC AMPH.O : BMO RAISES TARGET PRICE TO $19 FROM $17; 14/05/2018 – Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection; 12/03/2018 – Amphastar Pharmaceuticals 4Q Rev $60.4M

Cortina Asset Management Llc holds 0.32% of its portfolio in Amphastar Pharmaceuticals, Inc. for 352,170 shares. Argent Capital Management Llc owns 235,775 shares or 0.16% of their US portfolio. Moreover, Federated Investors Inc Pa has 0.06% invested in the company for 1.28 million shares. The New York-based Rothschild & Co Asset Management Us Inc. has invested 0.06% in the stock. Boston Advisors Llc, a Massachusetts-based fund reported 44,216 shares.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $1.01 billion. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Investors sentiment decreased to 1.12 in 2018 Q3. Its down 0.07, from 1.19 in 2018Q2. It worsened, as 22 investors sold CBL & Associates Properties, Inc shares while 55 reduced holdings. 35 funds opened positions while 51 raised stakes. 128.33 million shares or 1.84% more from 126.01 million shares in 2018Q2 were reported. Hexavest accumulated 13,286 shares. Amer Intl Group Incorporated reported 133,410 shares stake. Chicago Equity Prtn Ltd stated it has 0% of its portfolio in CBL & Associates Properties, Inc (NYSE:CBL). Ameritas Partners, a Nebraska-based fund reported 14,116 shares. Thrivent Fincl For Lutherans holds 120,834 shares or 0% of its portfolio. Rmsincerbeaux Cap Management Ltd invested in 0.7% or 217,496 shares. Prudential Finance has 907,207 shares. Credit Suisse Ag reported 0% in CBL & Associates Properties, Inc (NYSE:CBL). Robeco Institutional Asset Mngmt Bv reported 0.08% in CBL & Associates Properties, Inc (NYSE:CBL). Balyasny Asset Limited Liability Company holds 0.01% or 622,230 shares in its portfolio. Eqis Cap Mgmt has 25,022 shares for 0.01% of their portfolio. Us Bankshares De holds 2,816 shares. 754,508 were accumulated by Zweig. Orinda Asset Mngmt Limited Liability Company holds 0.66% or 81,679 shares. Zeke Advisors Limited has invested 0.01% in CBL & Associates Properties, Inc (NYSE:CBL).

Among 5 analysts covering CBL \u0026 Associates (NYSE:CBL), 0 have Buy rating, 4 Sell and 1 Hold. Therefore 0 are positive. CBL \u0026 Associates had 5 analyst reports since August 2, 2018 according to SRatingsIntel. The stock has “Sell” rating by Jefferies on Monday, November 26. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, August 2. The stock has “Underperform” rating by Bank of America on Monday, August 13. The firm earned “Sell” rating on Tuesday, August 7 by BTIG Research.

More notable recent CBL & Associates Properties, Inc (NYSE:CBL) news were published by: Seekingalpha.com which released: “REITs with Sears exposure jump as ESL puts forth alternative proposal – Seeking Alpha” on January 02, 2019, also Seekingalpha.com with their article: “REITs banged up badly in today’s selloff – Seeking Alpha” published on December 24, 2018, Seekingalpha.com published: “CBL: Balance Sheets Matter – Seeking Alpha” on October 30, 2018. More interesting news about CBL & Associates Properties, Inc (NYSE:CBL) were released by: Seekingalpha.com and their article: “CBL & Associates Properties declares $0.075 dividend – Seeking Alpha” published on October 29, 2018 as well as Seekingalpha.com‘s news article titled: “CBL is `always up for sale,’ CEO says – Seeking Alpha” with publication date: December 06, 2018.

CBL & Associates Properties, Inc (NYSE:CBL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.